English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Pancreatic cancer remains a challenging disease worldwide. Tanshinone IIA(Tan‑IIA) is one of the active constituents of Danshen (Radix Salviae miltiorrhizae).Tan‑IIA has been hypothesized to inhibit numerous human cancer cells by variousmolecular mechanisms. However, the efficacy and molecular mechanism of Tan‑IIAaction in pancreatic cancer has not been well studied. In the present study, thecytotoxicity of Tan‑IIA in human pancreatic cancer BxPC‑3 cells was evaluatedby MTT assay. Cell cycle analysis of BxPC‑3 cells treated with Tan‑IIA was performedby flow cytometry (FACS). Protein expression levels of TCTP, Mcl‑1, Bcl‑xL, Baxand Caspase‑3 in BxPC‑3 cells were measured by western blot analysis. The resultsrevealed that Tan‑IIA inhibited BxPC‑3 cells in a time‑ and dose‑dependent manner.FACS analysis demonstrated that Tan‑IIA increases the rate of sub‑G1 phase. BxPC‑3cells treated with Tan‑IIA were identified to upregulate protein expression ofBax and Caspase‑3 and downregulate expression of TCTP, Mcl‑1 and Bcl‑xL. Theseresults indicate that Tan‑IIA may inhibit BxPC‑3 human pancreatic cancer cellsthrough the induction of apoptosis by decreasing protein expression of TCTP, Mcl‑1and Bcl‑xL and increasing Bax expression in vitro. The chemotherapeutic potentialof Tan‑IIA for human pancreatic cancer warrants further study.

Tanshinone IIA inhibits the growth of pancreatic cancer BxPC-3 cells by decreasing protein expression of TCTP, MCL-1 and Bcl-xL